

# Jonathan R Emberson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1337633/jonathan-r-emberson-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130  
papers

31,177  
citations

52  
h-index

136  
g-index

136  
ext. papers

41,743  
ext. citations

16.7  
avg, IF

6.97  
L-index

#	Paper	IF	Citations
130	Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality: Prospective Study of 410 000 US Adults. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	4
129	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EClinicalMedicine</i> , <b>2021</b> , 41, 101163	11.3	1
128	Alcohol consumption and cause-specific mortality in Cuba: prospective study of 120 623 adults. <i>EClinicalMedicine</i> , <b>2021</b> , 33, 100692	11.3	2
127	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 199-208	18.8	87
126	Body-mass index, blood pressure, diabetes and cardiovascular mortality in Cuba: prospective study of 146,556 participants. <i>BMC Public Health</i> , <b>2021</b> , 21, 963	4.1	0
125	Sequencing of 640,000 exomes identifies variants associated with protection from obesity. <i>Science</i> , <b>2021</b> , 373,	33.3	22
124	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 693-704	59.2	4434
123	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> , 32, 127-137	12.7	9
122	Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults. <i>International Journal of Epidemiology</i> , <b>2021</b> , 50, 955-964	7.8	1
121	Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998-2004 and 2015-2019. <i>Diabetes Care</i> , <b>2021</b> , 44, 944-951	14.6	0
120	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2828-2839	5.6	1
119	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1179-1186	17.2	6
118	Association of Blood Pressure With Cause-Specific Mortality in Mexican Adults. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2018141	10.4	2
117	Association of childhood smoking and adult mortality: prospective study of 120 000 Cuban adults. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e850-e857	13.6	16
116	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1424-1437	12.3	13
115	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 47-60	6.9	18
114	Strategic Need for Large Prospective Studies in Different Populations. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 309-310	27.4	6

113	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2030-2040	59.2	628
112	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1345-1352	40	340
111	Hydroxychloroquine for COVID-19: Balancing contrasting claims. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 25-26	3.9	4
110	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , <b>2020</b> , 44, 2256-2266	5.5	3
109	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. <i>Lancet, The</i> , <b>2020</b> , 396, 381-389	40	305
108	Childhood Smoking, Adult Cessation, and Cardiovascular Mortality: Prospective Study of 390000 US Adults. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e018431	6	9
107	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1330-1341	27.4	1083
106	Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study. <i>Lancet Public Health, The</i> , <b>2019</b> , 4, e107-e115	22.4	15
105	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , <b>2019</b> , 393, 407-415	40	300
104	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2613-2623	40	77
103	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 643-652	24.1	43
102	Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Whole-Body Imaging: UK Biobank and Oxford BioBank. <i>Obesity</i> , <b>2019</b> , 27, 1200-1206	8	21
101	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1437-1449	9.5	46
100	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , <b>2019</b> , 96, 170-179	9.9	5
99	Cohort Profile: the Cuba Prospective Study. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 680-681e	7.8	4
98	General and Abdominal Adiposity and Mortality in Mexico City: A Prospective Study of 150000 Adults. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 397-405	8	8
97	RoB 2: a revised tool for assessing risk of bias in randomised trials. <i>BMJ, The</i> , <b>2019</b> , 366, l4898	5.9	3792
96	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 257-264	4.3	6

95	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 231-241	18.8	96
94	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , <b>2018</b> , 93, 1165-1174	9.9	16
93	Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial. <i>EBioMedicine</i> , <b>2018</b> , 31, 133-142	8.8	20
92	Cohort Profile: The Korean Cancer Prevention Study-II (KCPS-II) Biobank. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 385-386f	7.8	14
91	Impact of CKD on Household Income. <i>Kidney International Reports</i> , <b>2018</b> , 3, 610-618	4.1	16
90	Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 455-463	18.1	32
89	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , <b>2018</b> , 13, 175-189	6.3	26
88	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 1424-1434	8.7	13
87	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , <b>2018</b> , 93, 1000-1007	9.9	21
86	Adiposity and Blood Pressure in 110 000 Mexican Adults. <i>Hypertension</i> , <b>2017</b> , 69, 608-614	8.5	23
85	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , <b>2017</b> , 69, 314-322	8.5	19
84	Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1 Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D). <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	16
83	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 546-552	6.9	24
82	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 1671-1681	6.4	8
81	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , <b>2017</b> , 103, 1880-1890	5.1	16
80	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. <i>Stroke</i> , <b>2016</b> , 47, 2373-9	6.7	132
79	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , <b>2016</b> , 388, 2532-2561	14.5	961
78	Diabetes and Cause-Specific Mortality in Mexico City. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1961-1971	19.2	144

77	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 371-80	7.4	37
76	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. <i>Lancet Neurology</i> , <b>2016</b> , 15, 925-933	24.1	118
75	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 67, 31-9	7.4	26
74	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 67, 576-84	7.4	16
73	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. <i>Lancet</i> , <b>2016</b> , 387, 957-967	40	1638
72	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. <i>BMC Cancer</i> , <b>2016</b> , 16, 488	4.8	41
71	Are statins useful in patients with advanced chronic kidney disease? - AuthorsReply. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 971-972	18.1	6
70	Perioperative Rosuvastatin in Cardiac Surgery. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1744-53	59.2	186
69	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 829-39	18.1	158
68	Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial. <i>Maturitas</i> , <b>2015</b> , 80, 426-31	5	11
67	Thrombolysis in acute stroke--authorsReply. <i>Lancet</i> , <b>2015</b> , 385, 1396	40	5
66	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 602-12	7.4	146
65	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment TrialistsCollaboration. <i>American Heart Journal</i> , <b>2015</b> , 169, 605-12	4.9	35
64	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 591-601	7.4	97
63	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. <i>BMJ</i> , <b>2015</b> , 350, h1088	5.9	36
62	Evidence for the prevention and treatment of stroke in dialysis patients. <i>Seminars in Dialysis</i> , <b>2015</b> , 28, 35-47	2.5	35
61	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , <b>2015</b> , 16, 65	2.7	53
60	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet</i> , <b>2015</b> , 385, 1397-405	40	756

59	Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , <b>2014</b> , 64, 40-8	7.4	46
58	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1684-90	40	105
57	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. <i>Lancet, The</i> , <b>2014</b> , 384, 1929-35	40	1415
56	The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2014</b> , 9, 914-9	6.9	12
55	Effects of lowering LDL cholesterol on progression of kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1825-33	12.7	108
54	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. <i>Transplantation Research</i> , <b>2013</b> , 2, 7		20
53	Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. <i>European Heart Journal</i> , <b>2013</b> , 34, 1365-74	9.5	72
52	Statins for people at low risk of cardiovascular disease [AuthorsReply]. <i>Lancet, The</i> , <b>2012</b> , 380, 1817-1818	40	113
51	Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. <i>European Heart Journal</i> , <b>2012</b> , 33, 1571-81	9.5	33
50	Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001310	11.6	67
49	Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 1941-51	27.4	658
48	Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. <i>PLoS ONE</i> , <b>2012</b> , 7, e29849	3.7	225
47	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , <b>2011</b> , 79, 1331-40	9.9	468
46	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. <i>Lancet, The</i> , <b>2011</b> , 377, 469-76	40	132
45	Efficacy and safety of more intensive lowering of LDL cholesterol [AuthorsReply]. <i>Lancet, The</i> , <b>2011</b> , 377, 715-716	40	3
44	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 2181-92	40	1627
43	C-reactive protein in the Heart Protection Study [AuthorsReply]. <i>Lancet, The</i> , <b>2011</b> , 377, 1918-1919	40	5
42	Text messaging in smoking cessation: the txt2stop trial. <i>Lancet, The</i> , <b>2011</b> , 378, 6-7	40	16

41	Benefits of lowering cholesterol in chronic kidney disease [AuthorsReply]. <i>Lancet, The</i> , <b>2011</b> , 378, 1377-1378	4.0	1
40	Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. <i>PLoS ONE</i> , <b>2011</b> , 6, e25920	3.7	59
39	Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. <i>BMJ, The</i> , <b>2011</b> , 342, d1250	5.9	95
38	Serum free light chains and the risk of ESRD and death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 2829-37	6.9	25
37	Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. <i>American Journal of Kidney Diseases</i> , <b>2010</b> , 56, 1082-94	7.4	116
36	Stratification for exploring heterogeneity in systematic reviews. <i>Evidence-Based Medicine</i> , <b>2009</b> , 14, 162-4		5
35	The prevalence of chronic diseases and major disease risk factors at different ages among 150,000 men and women living in Mexico City: cross-sectional analyses of a prospective study. <i>BMC Public Health</i> , <b>2009</b> , 9, 9	4.1	34
34	Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19,000 men in the Whitehall study. <i>BMJ, The</i> , <b>2009</b> , 339, b3513	5.9	64
33	Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. <i>Lancet, The</i> , <b>2009</b> , 373, 1083-96	4.0	3015
32	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The</i> , <b>2009</b> , 373, 1849-60	4.0	2427
31	Aspirin in the primary prevention of vascular disease [ATT secretariat's reply]. <i>Lancet, The</i> , <b>2009</b> , 374, 879	4.0	
30	Ensuring trial validity by data quality assurance and diversification of monitoring methods. <i>Clinical Trials</i> , <b>2008</b> , 5, 49-55	2.2	104
29	Cholesterol, statins, and mortality [AuthorsReply]. <i>Lancet, The</i> , <b>2008</b> , 371, 1162-1163	4.0	1
28	Analyses of cancer data from three ezetimibe trials. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1357-66	59.2	190
27	Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. <i>European Heart Journal</i> , <b>2008</b> , 29, 800-9	9.5	38
26	Randomization is essential for progress in transplant medicine. <i>Transplantation</i> , <b>2008</b> , 86, 26-7	1.8	1
25	N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 311-9	15.1	93
24	Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 1373-8		56

23	A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. <i>Nephron Clinical Practice</i> , <b>2007</b> , 106, c104-12		20
22	Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. <i>Lancet, The</i> , <b>2007</b> , 370, 1829-39 <sup>40</sup>		1539
21	Cohort profile: the Mexico City Prospective Study. <i>International Journal of Epidemiology</i> , <b>2006</b> , 35, 243-97.8		33
20	Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 239-49	4.4	62
19	INTERHEART. <i>Lancet, The</i> , <b>2005</b> , 365, 117; author reply 118	40	3
18	Commentary: over-correction for regression dilution bias? Not for blood pressure vs coronary heart disease. <i>International Journal of Epidemiology</i> , <b>2005</b> , 34, 1368-9	7.8	
17	Social class differences in coronary heart disease in middle-aged British men: implications for prevention. <i>International Journal of Epidemiology</i> , <b>2004</b> , 33, 289-96	7.8	42
16	The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study. <i>Family Practice</i> , <b>2004</b> , 21, 582-6	1.9	19
15	Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2004</b> , 11, 125-34		61
14	The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error. <i>Journal of Clinical Epidemiology</i> , <b>2004</b> , 57, 1244-52	5.7	9
13	Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. <i>European Heart Journal</i> , <b>2004</b> , 25, 484-91	9.5	155
12	Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study. <i>Circulation</i> , <b>2003</b> , 107, 1260-4	16.7	228
11	Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. <i>European Heart Journal</i> , <b>2003</b> , 24, 1719-26	9.5	84
10	A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache. <i>Spine</i> , <b>2002</b> , 27, 1835-43; discussion 1843	3.3	485
9	Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. <i>Lancet, The</i> , <b>2001</b> , 357, 509-12	40	204
8	Effect of Dexamethasone in Hospitalized Patients with COVID-19 [Preliminary Report]		313
7	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial		82
6	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		4



5	Effect of vitamin D supplementation on biomarkers of inflammation and immune function: functional genomics analysis of the BEST-D trial	1
4	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	11
3	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	11
2	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	5
1	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	37